BRAF and colorectal cancer: Lonardi, S. et al.  First-line FOLFOX Plus Panitumumab Versus 5FU Plus Panitumumab in RAS-BRAF wild-type Metastatic Colorectal cancer Elderly Patients: the PANDA Study First-line FOLFOX Plus Panitumumab Versus 5FU Plus Panitumumab in RAS-BRAF wild-type Metastatic Colorectal cancer Elderly Patients: the PANDA Study  (American Society of Clinical Oncology, 2020).